Suivre
Colin G. Buss
Colin G. Buss
Harvard-MIT Health Sciences and Technology Program, Cambridge, MA 02139
Adresse e-mail validée de mit.edu
Titre
Citée par
Citée par
Année
Convergent multi-miRNA targeting of ApoE drives LRP1/LRP8-dependent melanoma metastasis and angiogenesis
N Pencheva, H Tran, C Buss, D Huh, M Drobnjak, K Busam, SF Tavazoie
Cell 151 (5), 1068-1082, 2012
4082012
Broad-spectrum therapeutic suppression of metastatic melanoma through nuclear hormone receptor activation
N Pencheva, CG Buss, J Posada, T Merghoub, SF Tavazoie
Cell 156 (5), 986-1001, 2014
1792014
Metastasis-suppressor transcript destabilization through TARBP2 binding of mRNA hairpins
H Goodarzi, S Zhang, CG Buss, L Fish, S Tavazoie, SF Tavazoie
Nature 513 (7517), 256-260, 2014
882014
Nanoparticle delivery of immunostimulatory oligonucleotides enhances response to checkpoint inhibitor therapeutics
CG Buss, SN Bhatia
Proceedings of the National Academy of Sciences 117 (24), 13428-13436, 2020
572020
Sustained‐Release Synthetic Biomarkers for Monitoring Thrombosis and Inflammation Using Point‐of‐Care Compatible Readouts
JS Dudani, CG Buss, RTK Akana, GA Kwong, SN Bhatia
Advanced functional materials 26 (17), 2919-2928, 2016
572016
Genome-scale analysis identifies paralog lethality as a vulnerability of chromosome 1p loss in cancer
SR Viswanathan, MF Nogueira, CG Buss, JM Krill-Burger, MJ Wawer, ...
Nature genetics 50 (7), 937-943, 2018
532018
Protease activity sensors noninvasively classify bacterial infections and antibiotic responses
CG Buss, JS Dudani, RTK Akana, HE Fleming, SN Bhatia
EBioMedicine 38, 248-256, 2018
282018
Lung protease nanosensors and uses thereof
SN Bhatia, J Kirkpatrick, JS Dudani, C Buss, AD Warren
US Patent App. 16/582,053, 2020
112020
Nanomaterial-mediated immune interactions for disease diagnosis and cancer immunotherapy
CG Buss
Massachusetts Institute of Technology, 2020
2020
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–9